Corcept Therapeutics (NASDAQ:CORT) Upgraded to Peer Perform at Wolfe Research

Wolfe Research upgraded shares of Corcept Therapeutics (NASDAQ:CORT) from an underperform rating to a peer perform rating in a report released on Thursday morning, MarketBeat.com reports.

CORT has been the subject of a number of other reports. Weiss Ratings reaffirmed a “hold (c)” rating on shares of Corcept Therapeutics in a research report on Monday, December 29th. UBS Group assumed coverage on Corcept Therapeutics in a research note on Tuesday, December 16th. They issued a “neutral” rating and a $95.00 price target on the stock. Canaccord Genuity Group raised their price target on Corcept Therapeutics from $99.00 to $100.00 and gave the company a “buy” rating in a report on Friday, January 23rd. Truist Financial raised shares of Corcept Therapeutics to a “strong-buy” rating in a research report on Wednesday. Finally, Zacks Research downgraded shares of Corcept Therapeutics from a “hold” rating to a “strong sell” rating in a report on Tuesday, January 13th. One equities research analyst has rated the stock with a Strong Buy rating, three have given a Buy rating, three have assigned a Hold rating and one has given a Sell rating to the stock. Based on data from MarketBeat, Corcept Therapeutics presently has an average rating of “Moderate Buy” and an average target price of $77.67.

Corcept Therapeutics Stock Down 4.8%

Corcept Therapeutics stock opened at $38.53 on Thursday. The company has a debt-to-equity ratio of 0.01, a current ratio of 2.92 and a quick ratio of 2.85. The company’s 50-day moving average is $37.47 and its 200-day moving average is $61.00. The firm has a market capitalization of $4.10 billion, a PE ratio of 46.99 and a beta of 0.29. Corcept Therapeutics has a fifty-two week low of $28.66 and a fifty-two week high of $117.33.

Corcept Therapeutics (NASDAQ:CORT) last posted its quarterly earnings results on Tuesday, February 24th. The biotechnology company reported $0.20 EPS for the quarter, missing analysts’ consensus estimates of $0.33 by ($0.13). The business had revenue of $202.13 million for the quarter, compared to the consensus estimate of $254.94 million. Corcept Therapeutics had a return on equity of 15.19% and a net margin of 12.96%.The company’s revenue for the quarter was up 11.1% on a year-over-year basis. During the same quarter in the previous year, the business posted $0.26 EPS. Sell-side analysts anticipate that Corcept Therapeutics will post 1.36 earnings per share for the current year.

Insider Activity at Corcept Therapeutics

In related news, insider William Guyer sold 20,000 shares of the business’s stock in a transaction on Tuesday, February 3rd. The stock was sold at an average price of $40.87, for a total value of $817,400.00. Following the completion of the sale, the insider directly owned 1,235 shares in the company, valued at $50,474.45. The trade was a 94.18% decrease in their position. The transaction was disclosed in a document filed with the SEC, which is available through the SEC website. Also, Director G Leonard Baker, Jr. acquired 100,000 shares of the firm’s stock in a transaction on Tuesday, March 17th. The stock was purchased at an average cost of $33.14 per share, for a total transaction of $3,314,000.00. Following the completion of the acquisition, the director owned 1,146,631 shares in the company, valued at approximately $37,999,351.34. This represents a 9.55% increase in their ownership of the stock. The SEC filing for this purchase provides additional information. Insiders sold 60,000 shares of company stock worth $2,241,035 in the last ninety days. 20.80% of the stock is owned by company insiders.

Institutional Investors Weigh In On Corcept Therapeutics

A number of hedge funds and other institutional investors have recently modified their holdings of CORT. Torren Management LLC acquired a new position in shares of Corcept Therapeutics in the fourth quarter valued at about $25,000. Advisory Services Network LLC bought a new stake in Corcept Therapeutics in the 3rd quarter valued at about $25,000. Clearstead Advisors LLC boosted its holdings in Corcept Therapeutics by 163.6% in the 3rd quarter. Clearstead Advisors LLC now owns 311 shares of the biotechnology company’s stock valued at $26,000 after purchasing an additional 193 shares during the period. Atlas Capital Advisors Inc. acquired a new position in shares of Corcept Therapeutics during the 4th quarter worth approximately $31,000. Finally, Hantz Financial Services Inc. grew its position in shares of Corcept Therapeutics by 113.7% during the 4th quarter. Hantz Financial Services Inc. now owns 985 shares of the biotechnology company’s stock worth $34,000 after purchasing an additional 524 shares in the last quarter. Institutional investors and hedge funds own 93.61% of the company’s stock.

More Corcept Therapeutics News

Here are the key news stories impacting Corcept Therapeutics this week:

• Positive Sentiment: FDA approval of Lifyorli (relacorilant) plus nab‑paclitaxel — the regulatory win is the primary commercial catalyst and triggered the recent multi‑day rally due to survival benefit data and earlier‑than‑expected decision. FDA Approves (BusinessWire)
• Positive Sentiment: Analyst/firm support: multiple firms raised or reiterated positive views (Truist to “strong‑buy”, Canaccord price target increase reported, HC Wainwright kept a Buy rating), which supports upside potential as the market prices in Lifyorli’s commercial opportunity. Analyst Coverage (Benzinga)
• Positive Sentiment: Insider confidence signal: market commentary highlighted a mid‑March purchase by a director (~100,000 shares) that likely helped amplify bullish positioning ahead of the approval. Insider Buy Analysis (QuiverQuant)
• Neutral Sentiment: Market structure/volatility: trading was temporarily halted (LULD pause) and the name has posted very large intraday moves as investors re‑price the company; expect elevated volume and short‑term volatility. Market Reaction Coverage (Reuters)
• Negative Sentiment: Multiple securities‑class‑action firms have filed/issued alerts alleging misstatements tied to prior FDA issues and patent litigation — several firms are seeking lead plaintiffs and note an April 21, 2026 deadline; these suits create tangible legal and financial overhang. Hagens Berman Alert (GlobeNewswire)
• Negative Sentiment: Recent insider selling: Corcept disclosed a sale by William Guyer (11,767 shares on Mar 20), which may be viewed negatively by some investors despite offsetting director purchases. Insider Sale SEC Filing

About Corcept Therapeutics

Corcept Therapeutics is a clinical-stage biopharmaceutical company focused on discovering and developing drugs that modulate the effects of cortisol, a hormone implicated in a range of severe metabolic, oncologic and psychiatric disorders. The company’s scientific platform centers on selectively targeting the glucocorticoid receptor to counteract the harmful consequences of excess cortisol, a strategy designed to address diseases with significant unmet medical needs.

The company’s flagship marketed product, Korlym (mifepristone), is approved in the United States for the treatment of hyperglycemia secondary to Cushing’s syndrome in patients who have type 2 diabetes or glucose intolerance and are not candidates for surgery.